TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials
In: Annals of Oncology, Jg. 27 (2016-10-01), S. vi523
Online
unknown
Zugriff:
Titel: |
TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials
|
---|---|
Autor/in / Beteiligte Person: | Bonetti, A. ; Giuliani, J. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 27 (2016-10-01), S. vi523 |
Veröffentlichung: | Elsevier BV, 2016 |
Medientyp: | unknown |
ISSN: | 0923-7534 (print) |
DOI: | 10.1093/annonc/mdw391.04 |
Schlagwort: |
|
Sonstiges: |
|